First Lady Melania Trump pushed Washington to take women’s health seriously across every stage of life. Less than two weeks later, that effort has produced another concrete result for women navigating menopause.

The Trump administration announced Friday that the Food and Drug Administration approved updated labeling for three additional menopausal hormone therapy products while working with manufacturers to expand supply.

The action removes outdated risk statements involving cardiovascular disease, breast cancer, and probable dementia from the boxed-warning section of three estradiol transdermal patches. It follows a scientific review of the therapies’ benefit-risk profiles, according to federal health officials.

HHS called the announcement a major win for women and credited President Trump and the first lady for putting menopause care on the administration’s agenda:

Three more products now have updated labeling, and the administration says production capacity is already moving in the right direction.

ADVERTISEMENT

The Department of Health and Human Services reports that 29 drug companies have submitted proposed labeling changes since the FDA began engaging manufacturers in November 2025. Six products received clarified labeling earlier this year, and Friday’s action adds three estradiol patches to that list.

The FDA says the changes reflect a fresh examination of the scientific literature and newer information about the therapies’ risks and benefits.

The agency is not telling every woman to use hormone therapy. It is updating the information women and their doctors use when deciding whether a treatment is appropriate.

An outdated warning can discourage a conversation before it begins. Current, accurate labeling lets patients and clinicians weigh the evidence without relying on language that federal regulators now say no longer reflects the science.

The FDA confirmed both sides of Friday’s action: updated labels and an effort to increase access as demand grows.

Federal officials anticipated that clearer labels could cause more women to seek treatments they had previously avoided. The FDA says it has been working directly with all six manufacturers of approved estradiol patches and is not currently aware of an imminent nationwide shortage.

Manufacturers have expanded capacity, added production shifts, and prioritized patch output. HHS says those steps have doubled overall market output during the last 12 months.

The agency is also exploring whether vaginal estrogen products could eventually be sold over the counter. That has not been approved.

Any switch would still require evidence that consumers can choose and use the products safely without a clinician supervising the decision.

ADVERTISEMENT

The latest action directly supports the women’s health executive order President Trump signed on October 19. Melania Trump was the driving force behind that order and the new White House Women’s Health Task Force.

The White House says the initiative is designed to close research and treatment gaps affecting women from childhood through pregnancy, midlife, menopause, and aging. It also creates a Women’s Health Division at the National Institutes of Health to coordinate research and move discoveries into patient care more quickly.

HHS connected Friday’s menopause announcement to that broader effort, highlighting a government-wide focus on women’s health at every stage of life:

For decades, women have heard politicians promise that overlooked health problems would finally receive attention. The Trump administration’s latest move is measurable: updated labels on three more therapies, a larger production pipeline, and continued pressure on regulators and manufacturers to improve access.

Women should still make treatment decisions with a qualified health professional who understands their medical history. But those conversations should be based on current evidence, not warnings the FDA has concluded are outdated.

Melania Trump put the issue on the president’s desk. Now the administration is turning that priority into action women can see.

This is a Guest Post from our friends over at WLTReport. View the original article here.

 

Join The Conversation. Leave a Comment.